British Society for Haematology. Listening. Learning. Leading British Society for Haematology. Listening. Learning. Leading
21 December 2018

A treatment under development for eye disease may also be effective against acute myeloid leukaemia (AML), British researchers have reported.

The discovery follows a detailed genetic analysis previously carried out at the Wellcome Sanger Institute, in Cambridge. The scientists discovered that a gene SRPK1 is essential for the development of a subtype of AML driven by rearrangements in the MLL gene.

SRPK1 is involved in RNA splicing – and the current study found that inhibiting it can kill AML cells. This led the scientists, in turn, to a compound called SPHINX31, which inhibits SRPK1. The compound is already being testing at the University of Nottingham as an eye drop treatment for retinal neovascular disease.

Pre-clinical studies in cell lines and mice both showed that SPHINX31 can stop the growth of MLL-rearranged AML cells but has no effect on normal blood stem cells. What’s more, mice treated with SPHINX31 showed no indication of side-effects, the researchers report in the journal Nature Communications.

They went on to show that the anti-AML effect was mediated in part by changes to the splicing of the RNA for BRD4, a gene which has already been associated with AML. Inhibiting SRPK1 causes the main form of BRD4 to switch to another form, a change which reduces AML growth.

Dr Konstantinos Tzelepis from the Wellcome Sanger Institute, joint leader of the research, said: “Our study describes a novel mechanism required for leukaemia cell survival and highlights the therapeutic potential of SRPK1 inhibition in an aggressive type of AML.”

He added: “Targeting this mechanism may be effective in other cancers where BRD4 and SRPK1 play a role, such as metastatic breast cancer.”


Source: Tzelepis, K., De Braekeleer, E., Aspris, D., Barbieri, I., Vijayabaskar, M. S., Liu, W.-H., Gozdecka, M., Metzakopian, E., Toop, H.D., Dudek, M., Robson, S.C., Hermida-Prado, F., Yang, Y.H., Babaei-Jadidi, R., Garyfallos, D.A., Ponstingl, H., Dias, J.M.L., Gallipoli, P., Seiler, M., Buonamici, S., Vick, B., Bannister, A.J., Rad, R., Prinjha, R.K., Marioni, J.C., Huntly, R., Batson, J., Morris, J.C., Pina, C., Bradley, A., Jeremias, I., Bates, D.O., Yusa, K., Kouzarides, T., Vassiliou, G.S. (2018) “SRPK1 maintains acute myeloid leukemia through effects on isoform usage of epigenetic regulators including BRD4”,  Nature Communications, available from doi: 10.1038/s41467-018-07620-0

 

Disclaimer: The news stories shared on this site are used as a way to inform our members and followers of updates and relevant information happening in Haematology. The BSH does not endorse the content of news items from external sources, and is not in a position to verify the findings, accuracy or the source of any studies mentioned. Any medical or drugs information is provided as an information resource only, and is not to be relied on for any diagnostic or treatment purposes.

News service provided by Englemed News http://www.englemed.co.uk/